Gopal Iyer
@drgopaliyer
Professor, Head and Neck Surgeon, Clinician-scientist, budding immunologist, trainee architect. Views expressed are my own & not reflective of my affiliations.
ID: 1391030476320559112
08-05-2021 14:01:41
1,1K Tweet
428 Followers
318 Following
Single protein makes the difference for this potential EV-based therapeutic #notvoodoo Elizabeth McKenna š¤£š¤£š¤£
Fundraising for cancer research and care!!! Daniel Tan Melvin LK CHUA | FRCR, PhD, FASCO Eliza Fong, Ph.D. Claramae Chia Valerie Chew
Exosomes making headlinesā¦ who would have ever thought!!! Bruce Ashford Vin Paleri Narayana Subramaniam Umamaheswar Duvvuri MD PhD straitstimes.com/singapore/s-poā¦
Shockingly accurate and universal!!!!! Bruce Ashford
Amazing meeting in Bali! A tour de force of intent by the Indonesia to drive cancer prevention and treatment for the next decade!!! #iicc Rebecca Dent
Greatest joy in getting together friends from all over the world Melvin LK CHUA | FRCR, PhD, FASCO Lį»±c Morris Edward Chow
Great review on gamma-delta T cells for cell therapy by my hardworking PhD student Weikiang Lim !! Thanks to ESMO IOTECH and John Haanen ddec1-0-en-ctp.trendmicro.com/wis/clicktime/ā¦
Our 2nd work supporting chromatin-related adaptation for acquired #Radioresistance in #HeadNeckCancer ! Collab with Edward Chow & talented PhD student Sharon_Chan using QPOP that serendipitously showed Panobinostat efficacy against RR HNC Mechanistic work identified HDAC6 as the
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langaā¦ Amazing work led by my colleagues!!
Nothing like hanging with friends from half way across the world, enjoying simple pleasures.. Walter Lee from dukeā¦ Kaisin Yee Umamaheswar Duvvuri MD PhD Bruce Ashford
Finally got my hands on the real thing!!! Vin Paleri Narayana Subramaniam Bruce Ashford Umamaheswar Duvvuri MD PhD
šKEYNOTE-689 Update at #AACR25 new standard? šNeoadjuvant + adjuvant #pembrolizumab in LA-HNSCC š EFS HR: 0.73 (95% CI 0.58ā0.92) š2-yr EFS: 75% vs 62% šCPS ā„10: HR 0.66 (95% CI 0.49ā0.88) āOS pendingānew standard? ARTICLE: oncologytube.com/pembrolizumab-ā¦ YouTube:
